EUCTR2012-003123-38-GR进行中（未招募）1 期
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Males or female patients aged 18 to 65 years, inclusive
- •2. Have had UC diagnosed at least 3 months prior to screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence
- •3. Have active UC confirmed on endoscopy with = 15 cm involvement
- •4. Have active UC defined as Mayo score of 6-12 inclusive with endoscopic subscore of = 2
- •5. Have undergone colonoscopy within the past 2 years for extent of disease, and if the UC has been present for > 10 years, have had a colonoscopy with biopsy to rule out dysplasia
- •6. Men and women of childbearing potential must agree to use adequate birth control measures during the study. Acceptable methods of birth control in this study include: surgical sterilization, intrauterine device, oral contraceptive, contraceptive patch, long acting injectable contraceptive, partner’s vasectomy, double-barrier method (condom or diaphragm with spermicide) or abstinence during study participation and for 30 days after their last dose of treatment of study treatment
- •7. Must be currently receiving treatment with at least 1 of the following therapies:
- •a. Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, balsalazide) for at least 6 weeks with the dose stable for at least 3 weeks prior to screening endoscopy
- •b. Prednisone (doses = 20 mg) or equivalent for at least 4 weeks and receiving a stable dose for at least 2 weeks
- •8. If oral aminosalicylates or corticosteroids have been recently discontinued, they must have been stopped for at least 2 weeks prior to the sigmoidoscopy used for baseline Mayo Score
- •9. All patients aged 45 years or over must have had a colonoscopy to screen for adenomatous polyps within 5 years of their first dose of study treatment or must have had a colonoscopy at screening to assess for polyps. The adenomatous polyps must be removed prior to their first dose of study drug.
- •10. Ability to provide written informed consent and to be compliant with the schedule of protocol assessments
- •11. Documentation of positive varicella zoster virus (VZV) IgG antibody status
- •12. Documentation of no evidence of chronic lung disease or tuberculosis (TB) on a chest X-ray completed within the 6 months prior to screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have severe extensive colitis evidenced by:
- •- Physician judgment that patient is likely to require colectomy or ileostomy within 12 weeks of baseline
- •- Current evidence of fulminant colitis, toxic megacolon or bowel perforation
- •- Previous total colectomy
- •- Have 4 or more of the following:
- •Temp > 38°C, Heart rate (HR) > 110 (bpm); Focal severe or rebound abdominal tenderness; Anemia (hemoglobin [Hgb] < 8.5 g/dL); Transverse colon diameter > 5cm on plain X-ray
- •2. Diagnosis of Crohn’s disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn’s disease
- •3. Have positive stool culture for pathogens (O+P, bacteria) or positive test for C. difficile at screening. If C. difficile is positive, the patient may be treated and retested
- •4. Have had treatment with cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 16 weeks of screening
- •5. Pregnancy, lactation, or a positive serum beta human chorionic gonadotrophin (hCG) measured during screening
- •6. Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric or other major systemic disease making implementation or interpretation of the study difficult or that would put the patient at risk
- •7. Clinically relevant cardiovascular conditions, including history or presence of ischemic heart disease, myocardial infarction, congestive heart failure, stroke, transient ischemic attack, sick sinus syndrome, recurrent syncope, second degree or higher atrioventricular (AV) block, prolonged QTcF interval (QT interval corrected for HR according to Fridericia's formula) (QTcF > 450 msec males, > 470 msec females), other clinically significant conduction abnormalities or any other significant cardiac condition that could jeopardize a patient’s health during the study in the opinion of the treating Investigator
- •8. Resting HR less than 55 beats per minute (bpm)
- •9. History of diabetes mellitus
- •10. History of uveitis
- •11. Known active bacterial, viral, fungal, mycobacterial infection or other infection (including TB or atypical mycobacterial disease [excluding fungal infection of nail beds]) or any major episode of infection that required hospitalization/treatment with intravenous (IV) antibiotics within 30 days or oral antibiotics within 14 days prior to screening
- •12. History or known presence of recurrent or chronic infection (e.g., hepatitis A, B, C or E, human immunodeficiency virus, syphilis, TB); recurring urinary tract infections are allowed
- •13. History of cancer, including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved)
- •14. History of alcohol or drug abuse within 1 year prior to randomization
- •15. History of or currently active primary or secondary immunodeficiency
- •16. History of treatment with any immune-modifying biologic agent including abatacept, infliximab, etanercept, adalimumab, anakinra, vedolizumab or golimumab within 4 months prior to randomization. Patients unresponsive to vedolizumab will be excluded.
- •17. History of treatment with a biologic
研究者
相似试验
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-HUCelgene International II Sàrl (CIS II).113
已完成
2 期
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS10017969Ulcerative colitisNL-OMON47857Celgene International II Sarl (CIS II)10
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-003123-38-PLCelgene International II Sàrl (CIS II)86
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-SKCelgene International II Sàrl (CIS II).86
进行中（未招募）
1 期
A CLINICAL EFFICACY AND SAFETY STUDY TO EVALUATE IN A BLINDED WAY THE NEW MEDICINAL PRODUCT RPC1063 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISModerately to severely active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2012-003123-38-BECelgene International II Sàrl (CIS II)86